Mirum Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 15, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 15, 2024

MIRM$93.18-0.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	Year Ended December 31,
	2023	2022	2021
Revenue:
Product sales, net	$178,874	$75,062	$3,138
License revenue	7,500	2,000	16,000
Total revenue	186,374	77,062	19,138
Operating expenses:
Cost of sales	47,039	12,374	1,903
Research and development	102,609	106,842	131,428
Selling, general and administrative	145,880	89,066	59,220
Total operating expenses	295,528	208,282	192,551
Loss from operations	(109,154)	(131,220)	(173,413)
Other income (expense):
Interest income	13,735	3,857	366
Interest expense	(15,105)	(15,979)	(17,590)
Change in fair value of derivative liability	—	906	(732)
Loss from termination of revenue interest purchase agreement	(49,076)	—	—
Gain from sale of priority review voucher, net	—	—	108,000
Other (expense) income, net	(2,824)	365	(582)
Net loss before provision for income taxes	(162,424)	(142,071)	(83,951)
Provision for (benefit from) income taxes	991	(6,406)	37
Net loss	$(163,415)	$(135,665)	$(83,988)
Net loss per share:
Basic	$(4.00)	$(4.01)	$(2.77)
Diluted	$(4.00)	$(4.02)	$(2.77)
Weighted-average shares outstanding:
Basic	40,885,124	33,839,072	30,321,722
Diluted	40,885,124	33,982,493	30,321,722

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.